﻿{"id":205,"date":"2007-01-01T00:00:01","date_gmt":"2007-01-01T00:00:01","guid":{"rendered":"https:\/\/awge.doctime.es\/?p=205"},"modified":"2016-05-24T08:23:54","modified_gmt":"2016-05-24T06:23:54","slug":"awge-213","status":"publish","type":"post","link":"https:\/\/awge.doctime.es\/index.php\/2007\/01\/01\/awge-213\/","title":{"rendered":"Transfusion-associated microchimerism: a new complication of blood transfusions in severely injured patients"},"content":{"rendered":"<div class='editorialPost'><strong>Editorial: Semin Hematol<\/strong><\/div>\n<div class='fechaPost'>Fecha: 01\/01\/2007<\/div>\n<div class='autorPost'>Reed W, Lee TH, Norris PJ, Utter GH, Busch MP.<\/div>\n<div class='enlacePost'><a href='http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?db=pubmed&#038;cmd=Retrieve&#038;dopt=AbstractPlus&#038;list_uids=17198844&#038;query_hl=13&#038;itool=pubmed_docsum' target='_blank'>Acceso al enlace publicador<\/a><\/div>\n<hr>\n<\/hr>\n<div class='resumenPost'>Microchimerism, the stable persistence of an allogeneic cell population, can result from allogeneic exposures including blood transfusion. Transfusion-associated microchimerism (TA-MC) appears to be a common but newly recognized complication of blood transfusion. Thus far TA-MC has been detected when severely injured patients are transfused. Injury induces an immunosuppressive and inflammatory milieu in which fresh blood products with replication-competent leukocytes can sometimes cause TA-MC. TA-MC is present in approximately half of transfused severely injured patients at hospital discharge and is not affected by leukoreduction. In approximately 10% of patients, the chimerism from a single blood donor may increase in magnitude over months to years, reaching as much as 2% to 5% of all circulating leukocytes. In this review, we discuss recent studies of TA-MC in the civilian trauma population and the potential for study of TA-MC in the military population, where the severity of injury and freshness of blood products suggest that TA-MC may be even more prominent. We also discuss the need for future studies to address the immunology of TA-MC, its stem cell biology, and its clinical manifestations that have the potential to be either pathologic (autoimmunity, graft-versus-host disease) or therapeutic (tolerance induction, various cell and gene therapies).\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Editorial: Semin Hematol Fecha: 01\/01\/2007 Reed W, Lee TH, Norris PJ, Utter GH, Busch MP. Acceso al enlace publicador Microchimerism,<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[4],"tags":[],"_links":{"self":[{"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/posts\/205"}],"collection":[{"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/comments?post=205"}],"version-history":[{"count":1,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/posts\/205\/revisions"}],"predecessor-version":[{"id":829,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/posts\/205\/revisions\/829"}],"wp:attachment":[{"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/media?parent=205"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/categories?post=205"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/awge.doctime.es\/index.php\/wp-json\/wp\/v2\/tags?post=205"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}